IPO Price Range: ₹96 - 101
Min Investment
₹1,21,200
IPO Size
₹29 Cr
IPO Status
Live
Quantity in 1 Lot
1200
Max Bid allowed
1
Listing Exchange
NSE
![]() | 14 May 2025 |
![]() | 16 May 2025 |
![]() | 19 May 2025 |
![]() | ₹29.75Cr |
![]() | 1200 |
Experienced Promoters and Management Team.
Consistently supplying quality products to our valued customers in time.
Continually improving the quality standards by implementing process control and prevention techniques.
Long-standing relationship with clients and suppliers.
Quality standards.
Legacy Business Process & Management.
Strong and experienced R&D team.
A significant portion of its revenue is derived from exports, and any decline in exportprofitability may adversely impact its overall financial performance.
The Company operates in pharmaceutical sector, which is extensively regulated, any failures onthe company part to comply with the existing and future statutory and/or regulatory requirements in the pharmaceutical sector could adversely affect its business, results of operations and financialcondition.
Its manufacturing units are subject to periodic inspections and audits by regulatory authoritiesand clients. Its may be subject to regulatory action which may damage the company reputation leading to an adverse effect on its business, results of operations, financial condition and cash flows.
The company has a very limited operating history as a Company, which may make it difficult for investors to evaluate its historical performance or future prospects.
The company has only one Manufacturing Facility, continued operations of its manufacturing facility is critical to the company business and any disruption in the operation of its manufacturing facility may have a material adverse effect on the company business, results of operations and financial condition.
The company generate a significant percentage of its revenue from few clients. The loss of any one or more of the company major clients would have a material adverse effect on its business operations and profitability.
Its inability to accurately forecast demand for the company products or manage its inventory or working capital requirements may have an adverse effect on the company business, results of operations and financial condition.
There was a Criminal litigation against its promoters cum directors and the company is not sure the same shall not be refiled by the concerned authority. In the event it is refiled, the interest of the promoters may divert from the business of the Company, which may adversely affect the business of the Company.
Its business operations are working capital intensive, and any inability to meet the company working capital requirements may adversely impact its financial condition and growth prospects.
The company has certain outstanding litigation against it, an adverse outcome of which may adversely affect its business, reputation and results of operations.
Investors | Holdings % |
Harshad Nanubhai Rathod | 24.07% |
Vivek Ashok Kumar Patel | 24.07% |
Mayur Popatlal Sojitra | 24.07% |
Hardik Mukundbhai Prajapati | 24.07% |
Ankita Vivek Patel | 0.93% |